The size of the global optogenetics market is estimated to value USD 122.00 billion by 2032 from USD 37.73 billion in 2024, growing at a CAGR of 15.80% from 2024 to 2032.
According to Pan American Health Organization (PAHO), the United States of America, Canada, Uruguay, Suriname, Honduras, Bolivia, and Cuba were among the countries with the highest number of deaths due to neurological conditions in 2019. According to the United Nations (UN), an estimated 1 billion people worldwide suffer from neurological conditions. The rising demand for light therapy treatment for treating chronic disease pain and the wide usage of optogenetics in the neurological field propel the global optogenetics market growth. Existing technological advancements such as wireless microchips and the growing use of optogenetics in neuroscience are favorable signals to the market's growth rate. As per the World Health Organization (WHO), in 2017, an estimated 300 million people were affected by depression globally which is the primary cause of disability.
The growing number of research institutes worldwide and rising awareness for effective treatment procedures propel the global optogenetics market growth. In addition, factors such as the growing prevalence of launching new applications in the biotechnology field with advanced technology and growth in the scale of healthcare centers are ascribed to drive the development of the global optogenetics market. The growing number of neuropsychiatric disorder cases is further expected to strengthen the market growth. According to Alzheimer’s Disease International, an estimated 55 million people worldwide lived with dementia in 2020, and it is estimated to reach 78 million by 2030 and 139 million by 2050. Diverse initiatives have been undertaken by the organizations such as NIH and WHO; these initiatives are expected to favor the growth rate of the market.
Furthermore, the available funds required for R&D activities and the growing incidences of mood disorders, depression, Parkinson's disease, and other related diseases are projected to accelerate the growth rate of the global optogenetics market. According to the Parkinson’s Foundation study report, around 60,000 Americans are diagnosed with Parkinson's disease yearly. About 10 million people had Parkinson's disease in 2016. In addition, the growing adoption rate of optogenetics technology in behavioral and neuroscience is another significant factor boosting the market growth.
The lack of comprehensive understanding and awareness about optogenetics among researchers, clinicians, and potential end-users is one of the major factors hampering the market growth. The high cost associated with the instruments and reagents, technological challenges and stringent regulations and ethical guidelines surrounding the use of optogenetics techniques further impede the market growth. Compatibility challenges, limited availability of skilled researchers and technicians proficient in genetics, neuroscience, optics, and data analysis and the regulatory landscape surrounding optogenetics research and its potential clinical applications inhibits the growth rate of the optogenetics market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Segments Covered |
By Type, Application, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis; Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Market Leaders Profiled |
Becton & Dickinson and Company (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Julphar (U.A.E.), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Ypsomed AG (Switzerland), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland) and Biodel Inc. (U.S.) |
Based on sensor type, the pH sensors segment is anticipated to show the fastest growth throughout the forecast period. The growing applications of optogenetics in neuroscience research and the increasing need to understand pH-dependent cellular mechanisms and their impact on neuronal function drive the growth of the pH sensors segment in the global optogenetics market.
The genetically encoded calcium indicators segment is another noteworthy segment among all and is estimated to grow at a healthy CAGR during the forecast period. The growing demand for calcium imaging techniques in neuroscience research, drug discovery, and understanding of brain disorders majorly propel the segmental growth. The ability of genetically encoded calcium indicators to visualize and monitor calcium dynamics in real time provides valuable insights into neural circuits and signaling pathways further boosting the growth rate of the segment.
Based on technique type, the channelrhodopsin segment is predicted to account for the major share of the global optogenetics market during the forecast period. The versatility and effectiveness of channelrhodopsin in modulating neuronal activity leads to a better understanding of neural circuits and their role in various neurological conditions primarily driving the growth of the channelrhodopsin segment in the global market.
The halorhodopsin segment is anticipated to account for a notable share of the global market during the forecast period. The growing interest in understanding the inhibitory processes in neural circuits and their implications in neurological disorders drives segmental growth.
Based on the application, the neuroscience segment is anticipated to hold the major share of the global market during the forecast period owing to the growing demand for advanced tools and techniques to study the brain, uncover its complexities and develop potential therapeutic interventions for neurological conditions.
The retinal disease treatment segment is expected to account for a notable share of the global market during the forecast period. The growing need for innovative treatments for retinal conditions such as retinitis pigmentosa and age-related macular degeneration where traditional treatments have limitations primarily drives segmental growth.
Based on light equipment, the LEDs segment is estimated to account for the major share of the global market during the forecast period. Since they are cheaper, smaller, more reliable, and easy to control, LEDs are found to surpass lasers in every aspect. They are integrated into implants, enabling the delivery of untethered light. However, the major downside and why they were not widely adopted in the optogenetics sector was the difficulty connecting the light with a high-efficiency fiber optic cable. Though single LEDs can emit as much as five watts of light, light is emitted in all directions, not in a coherent beam. These are among the main factors limiting the market segment's growth. However, a new group of fiber-coupled LEDs provides significantly higher fiber-coupled light intensities. Therefore, there are many advances in LED technologies and their implementations. For treating cutaneous and neurological diseases, efficient LED therapies are being used.
The laser segment is estimated to showcase a healthy CAGR during the forecast period. The rising need for targeted and localized control over neuronal activity in neuroscience research drives the demand for lasers in optogenetics and propel segmental growth. The growing number of advancements in laser technology, such as the development of compact and tunable lasers further contribute to the growth of the laser segment in the global market.
Geographically, the optogenetics market in North America held the major share of the worldwide market in 2023 and the lead of the North American region is expected to continue throughout the forecast period. The strong presence of key players, advanced research facilities and significant investments in research and development in the North American region contribute to the North American market growth. The high prevalence of neurological disorders, the increasing adoption of optogenetics techniques in neuroscience research, favorable government initiatives, supportive reimbursement policies and an increasing number of collaborations between academic institutions and industry players further propel the growth of the North American market. The U.S. market is one of the most significant countries worldwide for optogenetics. Neuroscience and optogenetics research activities are being conducted on a large scale in the North American region. Optogenetics in North America is expected to follow the general biotechnology market trends in the region.
The optogenetics market in Europe had the second-largest worldwide market share in 2023 and is predicted to grow at a healthy CAGR during the forecast period. The availability of well-established healthcare infrastructure, advanced research facilities, a large patient population with neurological disorders, the presence of leading research institutions and collaborations between academia and industry fuel the growth of the optogenetics market in Europe. Supportive government regulations and funding for research projects, increasing awareness about the potential applications of optogenetics further drive the optogenetics market growth in Europe. Germany and the UK are expected to control the major share of the European market in the coming years.
The Asia-Pacific optogenetics market is expected to be the fastest-growing regional market worldwide during the forecast period. Factors such as a large population base, increasing investments in healthcare infrastructure and rising awareness about neurological disorders fuel the growth of the APAC market. The growing number of advancements in research and development activities, increasing collaborations between research institutes and industry players and government initiatives to promote medical research and innovation contribute to the growth of the optogenetics market in the Asia-Pacific region. China led the market, followed by India in 2023 and the same trend is anticipated to continue throughout the forecast period.
The optogenetics market in Latin America held a considerable share of the global market in 2023 and is expected to pick up the pace during the forecast period. The growing prevalence of neurological disorders, increasing demand for advanced treatment options and improving healthcare infrastructure majorly contribute to the growth of the optogenetics market in the Latin American region. The growing investments in research and development and increasing awareness among healthcare professionals about the benefits of optogenetics further boost the growth rate of the Latin American market.
The MEA optogenetics market is anticipated to grow at a moderate CAGR in the coming years as this region is still in this technology's adoption phase. The rapid adoption of optogenetics techniques in research and clinical applications across MEA majorly drives the MEA market growth. The growing investments in healthcare infrastructure, growing research collaborations and rising awareness about neurological disorders drive the MEA market growth.
Some of the companies playing a leading role in the global optogenetics market profiled in this report are Coherent Inc., Noldus, Thorlabs Inc., Cobalt Inc., Scientifica, Bruker, Laserglow Technologies, Regenxbio Inc., Gensight, Addgene, UPenn Vector Core, and Jackson Laboratories.
By Sensor Type
By Techniques
By Application
By Light Equipment
By Region
Frequently Asked Questions
The global optogenetics market size was worth USD billion 32.58 in 2023.
During the forecast period, the global optogenetics market is expected to grow at a CAGR of 15.8%
North America captured the largest share of the global optogenetics market in 2023.
Coherent Inc., Noldus, Thorlabs Inc., Cobalt Inc., Scientifica, Bruker, Laserglow Technologies, Regenxbio Inc., Gensight, Addgene, UPenn Vector Core, and Jackson Laboratories are some of the noteworthy companies in the optogenetics market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region